Search - tctmd.com

Displaying 161 - 180 of 842

Sort: Relevancy | Date

Presentation TCT 2016

Hypertension Treatment Targets Beyond the Kidneys

Presenter: Felix Mahfoud, Michael A. Weber, Atul Pathak

October 30, 2016

Presentation TCT 2016

The Renal Nerves and Their Role in Hypertension: An Updated Synthesis (Anatomy and Pathophysiology)

Presenter: Felix Mahfoud, Michael A. Weber, Michael Joner

October 30, 2016

Presentation TCT 2016

Is There a Role for PCI of Renal Artery Stenosis in Hypertension Management?

Presenter: Felix Mahfoud, Michael A. Weber, Ehtisham Mahmud

October 30, 2016

Presentation TCT 2016

Whats Next for the Nurse/Tech Team?

Presenter: Regina Deible, Mary K. Egan

October 30, 2016

Presentation TCT 2016

Implications of Recent Hypertension Studies for Optimal BP Targets and Clinical Practice (SPRINT, PATHWAYS, Others)

Presenter: Felix Mahfoud, Michael A. Weber

October 30, 2016

Presentation TCT 2016

Evolution of the Nurse/Tech Role in the Cath Lab

Presenter: Regina Deible, Mary K. Egan

October 30, 2016

Presentation TCT 2016

Personalized Medicine Where Are We in 2016?

Presenter: Robert A. Harrington, A. Michael Lincoff, Clyde W. Yancy

October 30, 2016

Presentation TCT 2016

Anti-inflammatory Therapies for Atherosclerosis

Presenter: Robert A. Harrington, A. Michael Lincoff, Jean-Claude Tardif

October 30, 2016

Presentation TCT 2016

Heart Failure Advances (Ivabradine, ARNI, and More)

Presenter: Robert A. Harrington, A. Michael Lincoff, Clyde W. Yancy

October 30, 2016

Presentation TCT 2016

Diabetes Advances (SGLT-2, GLP-1, DPP4)

Presenter: Robert A. Harrington, A. Michael Lincoff, Norman E. Lepor

October 30, 2016

Presentation TCT 2016

Reversal of Chronic Anticoagulation: When, What, and How Effective?

Presenter: Paul A. Gurbel, James A. Reiffel

October 30, 2016

Presentation TCT 2016

Chronic Oral Anticoagulants: Limitations, Use Recommendations, and Investigational Agents

Presenter: Paul A. Gurbel, Christopher B. Granger

October 30, 2016

Presentation TCT 2016

Antiplatelet Agents: Limitations, Use Recommendations, and Investigational Agents

Presenter: David J. Moliterno

October 30, 2016

Presentation TCT 2016

Procedural Anticoagulants: Limitations, Use Recommendations and, Investigational Agents

Presenter: Paul A. Gurbel, Harvey D. White

October 30, 2016

Presentation TCT 2016

PCI Pharmacotherapy Considerations in Patients With Complicating Co-morbidities (CKD, Liver Disease, ASA Allergy, Prior Stroke, Thrombocytopenia)

Presenter: Sorin J. Brener, Franz-Josef Neumann, Sunil V. Rao

October 30, 2016

Presentation TCT 2016

Atrial Fibrillation Double vs Triple Therapy Considerations and Ongoing Trials

Presenter: Sorin J. Brener, Franz-Josef Neumann, Pascal Vranckx

October 30, 2016

Presentation TCT 2016

Pharmacotherapy for Hybrid PCI/CABG Cases

Presenter: Sorin J. Brener, Franz-Josef Neumann, Laura Mauri

October 30, 2016

Presentation TCT 2016

Limitations of Pharmacotherapy in Complicated PCI Anatomy (Diffuse CAD, Bifurcations, CAD, Calification, SVG, CTO, etc.)

Presenter: Sorin J. Brener, Franz-Josef Neumann, Usman Baber

October 30, 2016

Presentation TCT 2016

ACS Case Presentation: Where Pharmacotherapy Failed

Presenter: C. Michael Gibson, Daniel I. Simon, Gennaro Giustino

October 30, 2016

Presentation TCT 2016

Limitations of Pharmacotherapy Clinical Trial Design

Presenter: C. Michael Gibson, Daniel I. Simon, Sanjay Kaul

October 30, 2016

Advertisement

Hypertension Treatment Targets Beyond the Kidneys

The Renal Nerves and Their Role in Hypertension: An Updated Synthesis (Anatomy and Pathophysiology)

Is There a Role for PCI of Renal Artery Stenosis in Hypertension Management?

Whats Next for the Nurse/Tech Team?

Implications of Recent Hypertension Studies for Optimal BP Targets and Clinical Practice (SPRINT, PATHWAYS, Others)

Evolution of the Nurse/Tech Role in the Cath Lab

Personalized Medicine Where Are We in 2016?

Anti-inflammatory Therapies for Atherosclerosis

Heart Failure Advances (Ivabradine, ARNI, and More)

Diabetes Advances (SGLT-2, GLP-1, DPP4)

Reversal of Chronic Anticoagulation: When, What, and How Effective?

Chronic Oral Anticoagulants: Limitations, Use Recommendations, and Investigational Agents

Antiplatelet Agents: Limitations, Use Recommendations, and Investigational Agents

Procedural Anticoagulants: Limitations, Use Recommendations and, Investigational Agents

PCI Pharmacotherapy Considerations in Patients With Complicating Co-morbidities (CKD, Liver Disease, ASA Allergy, Prior Stroke, Thrombocytopenia)

Atrial Fibrillation Double vs Triple Therapy Considerations and Ongoing Trials

Pharmacotherapy for Hybrid PCI/CABG Cases

Limitations of Pharmacotherapy in Complicated PCI Anatomy (Diffuse CAD, Bifurcations, CAD, Calification, SVG, CTO, etc.)

ACS Case Presentation: Where Pharmacotherapy Failed

Limitations of Pharmacotherapy Clinical Trial Design

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content